Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Identifieur interne : 000F05 ( Main/Exploration ); précédent : 000F04; suivant : 000F06Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Auteurs : Kwan-Hwa Chi [Taïwan] ; Hui-Ling Ko [Taïwan] ; Kai-Lin Yang [Taïwan] ; Cheng-Yen Lee [Taïwan] ; Mau-Shin Chi [Taïwan] ; Shang-Jyh Kao [Taïwan]Source :
- Oncotarget [ 1949-2553 ] ; 2015.
Descripteurs français
- KwdFr :
- Administration métronomique, Adulte d'âge moyen, Autophagie (), Femelle, Humains, Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Mâle, Métastase tumorale (anatomopathologie), Métastase tumorale (traitement médicamenteux), Projets pilotes, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Relation dose-effet des médicaments, Résultat thérapeutique, Sirolimus (effets indésirables), Sirolimus (usage thérapeutique), Sujet âgé, Thérapie de rattrapage, Tumeurs (anatomopathologie), Tumeurs (traitement médicamenteux).
- MESH :
- anatomopathologie : Métastase tumorale, Tumeurs.
- effets indésirables : Hydroxychloroquine, Protocoles de polychimiothérapie antinéoplasique, Sirolimus.
- traitement médicamenteux : Métastase tumorale, Tumeurs.
- usage thérapeutique : Hydroxychloroquine, Protocoles de polychimiothérapie antinéoplasique, Sirolimus.
- Administration métronomique, Adulte d'âge moyen, Autophagie, Femelle, Humains, Mâle, Projets pilotes, Relation dose-effet des médicaments, Résultat thérapeutique, Sujet âgé, Thérapie de rattrapage.
English descriptors
- KwdEn :
- Administration, Metronomic, Aged, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Autophagy (drug effects), Dose-Response Relationship, Drug, Female, Humans, Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Male, Middle Aged, Neoplasm Metastasis (drug therapy), Neoplasm Metastasis (pathology), Neoplasms (drug therapy), Neoplasms (pathology), Pilot Projects, Salvage Therapy, Sirolimus (adverse effects), Sirolimus (therapeutic use), Treatment Outcome.
- MESH :
- chemical , adverse effects : Hydroxychloroquine, Sirolimus.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug effects : Autophagy.
- drug therapy : Neoplasm Metastasis, Neoplasms.
- pathology : Neoplasm Metastasis, Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Hydroxychloroquine, Sirolimus.
- Administration, Metronomic, Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects, Salvage Therapy, Treatment Outcome.
Abstract
Autophagy is an important oncotarget that can be modulated during anti-cancer therapy. Enhancing autophagy using chemotherapy and rapamycin (Rapa) treatment and then inhibiting it using hydroxychloroquine (HCQ) could synergistically improve therapy outcome in cancer patients. It is still unclear whether addition of Rapa and HCQ to chemotherapy could be used for reversing drug resistance.
DOI: 10.18632/oncotarget.3793
PubMed: 25944689
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000253
- to stream PubMed, to step Curation: 000253
- to stream PubMed, to step Checkpoint: 000260
- to stream Ncbi, to step Merge: 000292
- to stream Ncbi, to step Curation: 000292
- to stream Ncbi, to step Checkpoint: 000292
- to stream Main, to step Merge: 000F06
- to stream Main, to step Curation: 000F05
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.</title>
<author><name sortKey="Chi, Kwan Hwa" sort="Chi, Kwan Hwa" uniqKey="Chi K" first="Kwan-Hwa" last="Chi">Kwan-Hwa Chi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ko, Hui Ling" sort="Ko, Hui Ling" uniqKey="Ko H" first="Hui-Ling" last="Ko">Hui-Ling Ko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yang, Kai Lin" sort="Yang, Kai Lin" uniqKey="Yang K" first="Kai-Lin" last="Yang">Kai-Lin Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Cheng Yen" sort="Lee, Cheng Yen" uniqKey="Lee C" first="Cheng-Yen" last="Lee">Cheng-Yen Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chi, Mau Shin" sort="Chi, Mau Shin" uniqKey="Chi M" first="Mau-Shin" last="Chi">Mau-Shin Chi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kao, Shang Jyh" sort="Kao, Shang Jyh" uniqKey="Kao S" first="Shang-Jyh" last="Kao">Shang-Jyh Kao</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25944689</idno>
<idno type="pmid">25944689</idno>
<idno type="doi">10.18632/oncotarget.3793</idno>
<idno type="wicri:Area/PubMed/Corpus">000253</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000253</idno>
<idno type="wicri:Area/PubMed/Curation">000253</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000253</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000260</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000260</idno>
<idno type="wicri:Area/Ncbi/Merge">000292</idno>
<idno type="wicri:Area/Ncbi/Curation">000292</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000292</idno>
<idno type="wicri:Area/Main/Merge">000F06</idno>
<idno type="wicri:Area/Main/Curation">000F05</idno>
<idno type="wicri:Area/Main/Exploration">000F05</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.</title>
<author><name sortKey="Chi, Kwan Hwa" sort="Chi, Kwan Hwa" uniqKey="Chi K" first="Kwan-Hwa" last="Chi">Kwan-Hwa Chi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ko, Hui Ling" sort="Ko, Hui Ling" uniqKey="Ko H" first="Hui-Ling" last="Ko">Hui-Ling Ko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yang, Kai Lin" sort="Yang, Kai Lin" uniqKey="Yang K" first="Kai-Lin" last="Yang">Kai-Lin Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Cheng Yen" sort="Lee, Cheng Yen" uniqKey="Lee C" first="Cheng-Yen" last="Lee">Cheng-Yen Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chi, Mau Shin" sort="Chi, Mau Shin" uniqKey="Chi M" first="Mau-Shin" last="Chi">Mau-Shin Chi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kao, Shang Jyh" sort="Kao, Shang Jyh" uniqKey="Kao S" first="Shang-Jyh" last="Kao">Shang-Jyh Kao</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Oncotarget</title>
<idno type="eISSN">1949-2553</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Metronomic</term>
<term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Autophagy (drug effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Humans</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Metastasis (drug therapy)</term>
<term>Neoplasm Metastasis (pathology)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (pathology)</term>
<term>Pilot Projects</term>
<term>Salvage Therapy</term>
<term>Sirolimus (adverse effects)</term>
<term>Sirolimus (therapeutic use)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration métronomique</term>
<term>Adulte d'âge moyen</term>
<term>Autophagie ()</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Mâle</term>
<term>Métastase tumorale (anatomopathologie)</term>
<term>Métastase tumorale (traitement médicamenteux)</term>
<term>Projets pilotes</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Sirolimus (effets indésirables)</term>
<term>Sirolimus (usage thérapeutique)</term>
<term>Sujet âgé</term>
<term>Thérapie de rattrapage</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Métastase tumorale</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Autophagy</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Metastasis</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasm Metastasis</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Hydroxychloroquine</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Métastase tumorale</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hydroxychloroquine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Metronomic</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Salvage Therapy</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration métronomique</term>
<term>Adulte d'âge moyen</term>
<term>Autophagie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Projets pilotes</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Thérapie de rattrapage</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Autophagy is an important oncotarget that can be modulated during anti-cancer therapy. Enhancing autophagy using chemotherapy and rapamycin (Rapa) treatment and then inhibiting it using hydroxychloroquine (HCQ) could synergistically improve therapy outcome in cancer patients. It is still unclear whether addition of Rapa and HCQ to chemotherapy could be used for reversing drug resistance.</div>
</front>
</TEI>
<affiliations><list><country><li>Taïwan</li>
</country>
</list>
<tree><country name="Taïwan"><noRegion><name sortKey="Chi, Kwan Hwa" sort="Chi, Kwan Hwa" uniqKey="Chi K" first="Kwan-Hwa" last="Chi">Kwan-Hwa Chi</name>
</noRegion>
<name sortKey="Chi, Mau Shin" sort="Chi, Mau Shin" uniqKey="Chi M" first="Mau-Shin" last="Chi">Mau-Shin Chi</name>
<name sortKey="Kao, Shang Jyh" sort="Kao, Shang Jyh" uniqKey="Kao S" first="Shang-Jyh" last="Kao">Shang-Jyh Kao</name>
<name sortKey="Ko, Hui Ling" sort="Ko, Hui Ling" uniqKey="Ko H" first="Hui-Ling" last="Ko">Hui-Ling Ko</name>
<name sortKey="Lee, Cheng Yen" sort="Lee, Cheng Yen" uniqKey="Lee C" first="Cheng-Yen" last="Lee">Cheng-Yen Lee</name>
<name sortKey="Yang, Kai Lin" sort="Yang, Kai Lin" uniqKey="Yang K" first="Kai-Lin" last="Yang">Kai-Lin Yang</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:25944689 |texte= Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25944689" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |